Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial

Objectives To evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III randomised study of Japanese patients with episodic migraine (EM) or chronic migraine (CM).Design Multicentre open-label study.Setting A total...

Full description

Bibliographic Details
Main Authors: Koichi Hirata, Fumihiko Sakai, Miki Hasebe, Takao Takeshima, Yotaro Numachi, Ryuji Yoshida, Reija Koukakis, Daishi Yui, Gabriel Paiva da Silva Lima, Sunfa Cheng
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/8/e068616.full

Internet

https://bmjopen.bmj.com/content/13/8/e068616.full

Similar Items